Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two PEG-rhGH Preparations in Healthy Adults
NCT06840691Phase 1Not yet recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- May 2025
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of peg-somatropin in growth hormone deficiency (GHD) (3 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Peak Plasma Concentration, Area Under the Concentration-Time Curve from Time Zero to Infinity and 1 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
peg-somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT06840691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840691.